Paul J Joudrey1, Benjamin J Oldfield2, Kimberly A Yonkers3, Patrick G O'Connor2, Gretchen Berland2, E Jennifer Edelman2. 1. VA Connecticut Healthcare System, West Haven Campus, 950 Campbell Ave, West Haven, CT, 06516, United States; Department of Internal Medicine, Yale School of Medicine, Yale University, 367 Cedar Street, New Haven, CT, United States. Electronic address: paul.joudrey@yale.edu. 2. Department of Internal Medicine, Yale School of Medicine, Yale University, 367 Cedar Street, New Haven, CT, United States. 3. Department of Psychiatry, Yale School of Medicine, 40 Temple Street, Ste Suite 6B, New Haven, CT, 06510, United States.
Abstract
BACKGROUND: Although the inpatient setting presents an important opportunity for medications for alcohol use disorder (MAUD) adoption, this infrequently occurs. We aimed to develop a comprehensive understanding of barriers and facilitators of inpatient MAUD adoption. METHODS: A convergent mixed-method study conducted from April to September 2018 of non-prescribing (registered nurse, pharmacist, and social work) and prescribing (physician or advanced practice provider hospitalist, general internist, and psychiatrist) professionals at a large urban academic medical center. Survey assessed organizational readiness to adopt MAUD and focus groups guided by the Consolidated Framework for Implementation Research (CFIR) analyzed using directed content analysis. RESULTS: Fifty-seven participants completed surveys and one of seven focus groups. Health professionals perceived clinical evidence (mean 4.0, 95 % confidence interval [CI]: 3.9, 4.2) as supportive and patient preferences (mean 3.4, 95 % CI: 3.2, 3.6) and availability of resources (mean 3.1, 95 % CI: 2.8, 3.3) as less supportive of MAUD adoption. Stakeholders identified barriers across CFIR constructs; 1) Intervention characteristics: limited knowledge of MAUD effectiveness and concerns about side effects, 2) Outer setting: perceived patient vulnerability to care interruptions and a lack of external incentives, 3) Inner setting: a lack of organizational prioritization, and 4) Characteristics of individuals: stigma of people with AUD. Facilitators included: 1) Intervention characteristics: adaptation of workflows and 2) Characteristics of individuals: harm reduction as treatment goal. CONCLUSIONS: This study identified multiple intersecting barriers and facilitators of inpatient MAUD adoption. Implementation interventions should prioritize strategies that increase health professional knowledge of MAUD and organizational prioritization of treating AUD.
BACKGROUND: Although the inpatient setting presents an important opportunity for medications for alcohol use disorder (MAUD) adoption, this infrequently occurs. We aimed to develop a comprehensive understanding of barriers and facilitators of inpatient MAUD adoption. METHODS: A convergent mixed-method study conducted from April to September 2018 of non-prescribing (registered nurse, pharmacist, and social work) and prescribing (physician or advanced practice provider hospitalist, general internist, and psychiatrist) professionals at a large urban academic medical center. Survey assessed organizational readiness to adopt MAUD and focus groups guided by the Consolidated Framework for Implementation Research (CFIR) analyzed using directed content analysis. RESULTS: Fifty-seven participants completed surveys and one of seven focus groups. Health professionals perceived clinical evidence (mean 4.0, 95 % confidence interval [CI]: 3.9, 4.2) as supportive and patient preferences (mean 3.4, 95 % CI: 3.2, 3.6) and availability of resources (mean 3.1, 95 % CI: 2.8, 3.3) as less supportive of MAUD adoption. Stakeholders identified barriers across CFIR constructs; 1) Intervention characteristics: limited knowledge of MAUD effectiveness and concerns about side effects, 2) Outer setting: perceived patient vulnerability to care interruptions and a lack of external incentives, 3) Inner setting: a lack of organizational prioritization, and 4) Characteristics of individuals: stigma of people with AUD. Facilitators included: 1) Intervention characteristics: adaptation of workflows and 2) Characteristics of individuals: harm reduction as treatment goal. CONCLUSIONS: This study identified multiple intersecting barriers and facilitators of inpatient MAUD adoption. Implementation interventions should prioritize strategies that increase health professional knowledge of MAUD and organizational prioritization of treating AUD.
Authors: Emily C Williams; Carol E Achtmeyer; Jessica P Young; Douglas Berger; Geoffrey Curran; Katharine A Bradley; Julie Richards; Michael B Siegel; Evette J Ludman; Gwen T Lapham; Mark Forehand; Alex H S Harris Journal: J Gen Intern Med Date: 2017-10-30 Impact factor: 5.128
Authors: Laura J Damschroder; David C Aron; Rosalind E Keith; Susan R Kirsh; Jeffery A Alexander; Julie C Lowery Journal: Implement Sci Date: 2009-08-07 Impact factor: 7.327
Authors: Honora Englander; Konrad Dobbertin; Bonnie K Lind; Christina Nicolaidis; Peter Graven; Claire Dorfman; P Todd Korthuis Journal: J Gen Intern Med Date: 2019-12 Impact factor: 5.128
Authors: Kim Donoghue; Catherine Elzerbi; Rob Saunders; Craig Whittington; Stephen Pilling; Colin Drummond Journal: Addiction Date: 2015-03-17 Impact factor: 6.526
Authors: Paul J Joudrey; Christina R Nelson; Kelly Lawson; Kenneth L Morford; Dakibu Muley; Cynthia Watson; Martha Okafor; Emily A Wang; Cindy Crusto Journal: J Subst Abuse Treat Date: 2021-05-14
Authors: E Jennifer Edelman; Geliang Gan; James Dziura; Denise Esserman; Kenneth L Morford; Elizabeth Porter; Philip A Chan; Deborah H Cornman; Benjamin J Oldfield; Jessica E Yager; Srinivas B Muvvala; David A Fiellin Journal: J Acquir Immune Defic Syndr Date: 2021-07-01 Impact factor: 3.771